Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 26, 2026.

Atrial fibrillation and microRNAs

Gaetano Santulli, Guido Iaccarino, Nicola De Luca and 2 more

Frontiers in Physiology · 2014 · Review

doi:10.3389/fphys.2014.00015

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia, especially in the elderly, and has a significant genetic component. Recently, several independent investigators have demonstrated a functional role for small non-coding RNAs (microRNAs) in the pathophysiology of this cardiac arrhythmia. This report represents a systematic and updated appraisal of the main studies that established a mechanistic association between specific microRNAs and AF, focusing both on the regulation of electrical and structural remodeling of cardiac tissue.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

MicroRNA

MicroRNAs (miRs) are an evolutionarily conserved class of small (~22 nucleotides) non-coding RNAs (Ambros,; Gan et al., ), first discovered in Caenorhabditis elegans (Ruvkun and Giusto,; Ruvkun et al., ). They represent a vital component of genetic regulation, existing in virtually all organisms, suggesting thereby a pivotal role in biological processes (Latronico and Condorelli,; Thum et al., ). Indeed, miRs are important regulators of gene expression in numerous biological processes including cellular proliferation, differentiation, and tumorigenesis (Care et al.,; Dvinge et al.,; Shen et al.,; Song et al., ). Typically, miRs are regarded as negative regulators of gene expression that inhibit translation and/or promote mRNA degradation by base pairing to complementary sequences within the 3′-untranslated region (3′-UTR) of protein-coding mRNA transcripts (Van Rooij and Olson,; Meijer et al., ). Generally, mRNA degradation accounts for the majority of miR activity (Guo et al., ). Hence, by altering levels of key regulators within complex genetic pathways, miRs provide a posttranscriptional level of control of homeostatic and developmental events (Callis et al.,; Yates et al., ).

It is estimated that miRs regulate over 60% of all protein-coding genes (Friedman et al.,; Akerman and Mukherjee,; Leucci et al., ). Considering that a single miR can regulate multiple mRNAs and that each mRNA may be a target of multiple miRs, the possible pathways for miR-dependent regulation of protein abundance seem to be extremely complicated (Akerman and Mukherjee,; Santulli and Totary-Jain, ). In this model, a biologic response would be expected only after co-expression of various miRs that cooperatively target different components of a functional network (Liu et al.,; Van Rooij and Olson, ) or are all required to sufficiently repress a single target (Lagos-Quintana et al.,; Kim, ).

Biogenesis and biological action of miRs

Maturation of miRs involves a multi-stepped process (Bartel,; Cullen, ) that starts from the transcription (mainly operated by RNA polymerase II) of single-stranded non-protein-coding RNAs, which are either transcribed as stand alone transcripts (intergenic miRs), often encoding various miRs, or generated by the processing of introns of protein-coding genes (intragenic or intronic miRs).

Transcription of intergenic miRs leads to the formation of primary miRs (pri-miR) with a characteristic hairpin or stem-loop structure (Denli et al., ), which are subsequently processed by the nuclear RNase III, Drosha (Zeng et al., ), and its partner proteins, among which there is the DiGeorge Syndrome Critical Region 8 (DGCR8, known as Pasha in invertebrates), named for its association with DiGeorge Syndrome (Shiohama et al.,; Roth et al., ), to become precursor miR s (pre-miR). On the other hand, intronic miRs are obtained by the regular transcription of their host genes and then spliced to form looped pre-miRs, bypassing thereby the Drosha pathway (Bartel,; Ruby et al., ).

Pre-miRs are exported from the nucleus in the cytoplasm in a process involving the Ran-GTP-dependent shuttle Exportin-5 (Lund et al., ). Once in the cytosol, the pre-miR hairpin is cleaved by the RNase III enzyme Dicer (Saxena and Tabin,; Marasovic et al., ), yielding a mature miR:miR* duplex about 22 nucleotides in length, which is subsequently incorporated into the protein complex called RNA-induced silencing complex (RISC) to form miRISC (Filipowicz et al.,; Wu et al., ). At this point, one of the double strands, the guide strand, is selected by the argonaute protein (Pfaff et al., ), the catalytically active RNase in the RISC complex, on the basis of the thermodynamic stability of the 5′ end. In particular, the strand with a less thermodynamically stable 5′ end is commonly chosen and loaded into the RISC complex (Siomi and Siomi, ), serving as a guide for mRISC to find its complementary motifs in the 3′-UTR of the target mRNA(s). Although either strand of the mature duplex may potentially act as a functional miR, only one strand is usually incorporated into the RISC where the miR and its mRNA target interact (Fabian and Sonenberg,; Von Brandenstein et al., ). Such a binding inhibits the translation of the protein that the target mRNA encodes or promotes gene silencing via mRNA degradation (Latronico and Condorelli,; Kallen et al.,; Papait et al., ).

In the human genome more than 1200 miR sequences have been identified, hitherto [miRTarBase, Release 4.5, version 20 (Hsu et al., )], with over 50,000 miR-target interactions. Recently, several algorithms and bioinformatics websites, including TargetScan and miRWalk (Lewis et al.,; Dweep et al., ) have been developed to predict specific mRNA/miR interactions. However, miR-binding rules are quite complex and are not fully understood, resulting in a lack of consensus in the literature.

Given all these crucial features, miRs could represent an important way for the cell to establish intercellular (with other cells, via secreted miRs) and intracellular (among its own genes) communication.

Establishing direct cause-and-effect links between miRs and mRNA targets is essential to understanding the molecular mechanisms underlying disease and the subsequent development of targeted therapies (Ambros et al.,; Zacharewicz et al., ).

Atrial fibrillation

Atrial fibrillation (AF) is a highly prevalent disease with a significant genetic component (Den Hoed et al.,; Mahida,; Santulli, ), considered the most common sustained arrhythmia, which can cause or exacerbate heart failure and represents an important risk factor for ischemic stroke (Fye,; Conen et al.,; Santulli,; Santulli et al.,; Thomas and Sorrentino, ). AF represents the most commonly seen arrhythmia worldwide, especially in the geriatric population (Huikuri,; Riley and Manning,; Santulli et al.,; Santulli and Iaccarino, ) and is associated with a substantially pronounced morbidity and mortality (Beyerbach and Zipes,; Santulli,; Garg and Akoum,; Menezes et al., ). From a pathophysiological point of view, AF is characterized by atrial electrical remodeling, mainly mediated by ion-channel alterations (Brundel et al.,; Santulli et al.,; Xie et al., ) and structural remodeling (fibrosis and apoptosis), which favors arrhythmia recurrence and maintenance (Perino et al.,; Santulli and D'Ascia,; Santulli et al., ). A noticeable feature of the electrical remodeling associated with AF is the abbreviation of the effective refractory period favoring reentry (D'Ascia et al.,,; Kapur and Macrae, ), primarily due to shortening of atrial action potential duration (APD).

Three potential models have been proposed to explain the pathophysiology of AF (Jalife, ), albeit the precise relationship of each of these conceptual frameworks to human AF remains under investigation (Vikman et al.,; Kapur and Macrae,; Shah et al., ):

The focal mechanism theory suggests that AF is provoked by the rapid firing of single or multiple ectopic foci, and also proposes a functional role for continued ectopic firing in the maintenance of AF (Lee et al., ).

The single circuit re-entry theory of AF assumes the presence of a single dominant reentry circuit alongside with the fragmentation of emanating waves in the heterogeneous electrical substrate of normal atrial tissue (Zemlin and Pertsov,; Kapur and Macrae, ).

The multiple wavelet theory of AF stands on the notion that multiple reentry circuits exist, with randomly propagating wavefronts that must find receptive tissue in order to persist (Haissaguerre et al., ).

Slowing of conduction velocities and shortening of the refractory period of atrial myocytes (both central features of the electrical remodeling seen in AF) might help to stabilize the arrhythmia by decreasing circuit size. Of course these mechanistic models are not mutually exclusive. They may coexist in a single subject at various stages in the pathogenesis of AF and each may be applicable to certain subgroups of AF patients (Lindgren et al.,; Brieger and Freedman,; Ruwald et al., ). Theoretically, all the miRs that are directly or indirectly involved in one of these processes, which are eventually based on the regulation of structural or electrical remodeling (cardiac automaticity, ion channels, fibrosis, and apoptosis), could participate in AF induction or perpetuation.

Experimental strategy to identify miRs involved in human disease

The most common experimental approach to identify the specific miRs that play a role in a certain disease mainly consists of three phases: (1) Use a microarray matrix to recognize a list of miRs that are differentially expressed in subjects with the disease compared to control subjects (Frezzetti et al.,; Jayaswal et al., ); (2) assess the putative target site efficacy by using bioinformatics-based algorithms or other computational tools that score potential interactions between microRNAs and mRNAs (Witkos et al., ); (3) validate in vitro (or in vivo) the existence of an inverse correlation between the expression levels of the miR and protein levels of its target gene(s). Another biological validation could be also achieved using a reporter system or other assays to prove that the binding of the miR and the target mRNA occurs within a RISC complex (Ling et al., ).

Functional role of miRs in atrial fibrillation

Growing evidence demonstrates that miRs regulate several properties of cardiac physiology and excitability, including automaticity, Ca2+ handling, conduction, and repolarization (Grueter et al.,; Boon et al.,; Heymans et al.,; Latronico and Condorelli, ). In particular, recent reports have unveiled an essential role of miRs in regulating cardiac excitability and arrhythmogenesis (Callis et al.,; Shan et al., ). These studies have primarily focused on the two muscle-specific miRs, i.e., miR-1 and miR-133, which are among the most abundantly expressed miRs in the heart (Liang et al.,; Wang et al., ).

However, lately other ubiquitously distributed miRs, such as miR-328 have been shown to exhibit a strong arrhythmogenic potential (Lu et al., ). It is likely that multiple miRs contribute to controlling arrhythmogenicity of the heart and that different miRs are involved in different types of arrhythmias under different pathological conditions of the heart (Horie et al.,; Kochegarov et al.,; Qiao et al.,; Zhang et al., ). The most important miRs so far implicated in the pathophysiology of AF, regulating both electrical and structural remodeling, are reported in Table 1, alongside with their target gene(s) and function(s).

Although circulating miRs seem to be interesting candidates as biomarkers in AF patients, they still possess several important limitations (Quiat and Olson,; Santulli and Totary-Jain, ). Indeed, at the moment there is no good natural stable housekeeping control for circulating miRs, which may result in strong variations, and they are generally present in low amounts in plasma and serum.

Regulation of proteins involved in electrical remodeling by miRs

As mentioned above, arrhythmogenesis is essentially attributed to enhanced triggered activity, and several studies have attributed such activity to alterations in different ion channels, including a peculiar instability in Ca2+ handling (Ter Keurs and Boyden,; Zhang et al.,; Latronico and Condorelli,; Kushnir and Marks,; Nivala et al., ) and modulation of the cardiac inwardly rectifying K+ current (IK1), which stabilizes the resting membrane potential, controls cardiac excitability, regulates late-phase repolarization, and is thereby responsible for shaping the initial depolarization and final repolarization of the action potential (Dhamoon and Jalife, ).

In a seminal study, the expression of miR-1 was demonstrated to be reduced by ~86% in tissue samples of AF patients (Girmatsion et al., ). This miR has been shown to be mechanistically critical in the pathophysiology of AF via targeting IK1 and connexin43 (Girmatsion et al., ), both considered master regulators of cardiac conduction (Delmar and Makita,; Musa et al., ). Similarly, miR-26 has the potential to repress IK1 (Luo et al., ). Intriguingly, in the setting of ventricular arrhythmias miR-1 levels appear to be augmented (Anderson and Mohler,; Yang et al., ). Thus, the different regulation of such a miR in ventricular and atrial tissue deserves further investigations (Anderson and Mohler,; Yang et al.,; Santulli et al., ). The recently proposed involvement of miR-1 in the modulation of Ca2+ handling proteins, including calmodulin, phospholamban, Na+/Ca2+ exchanger (NCX), sorcin, junctin, triadin, eventually resulting in shortened refractoriness of sarcoplasmic reticulum Ca2+ release further support the hypothesis of a pivotal functional role of such a miR in the pathogenesis of AF (Ali et al.,; Karakikes et al.,; Slagsvold et al.,; Tritsch et al.,; Zhang et al., ).

Lu et al. demonstrated that miR-328 level was elevated in AF patients and identified as target genes CACNA1C and CACNB1, encoding L-type Ca2+ channel subunits. Thereby, increased levels of miR-328 reduce ICaL density and shorten APD, leading to an increased arrhythmogenic potential. Additionally, miR-223, miR-328, and miR-664 were found to be upregulated by >2 fold in AF samples (Lu et al., ), and further investigations are required to establish the molecular mechanism underlying such a change in the miR transcriptome.

Most recently, Ling and colleagues found a strong association between mir-499, which is significantly up-regulated in atrial tissue from AF patients, and KCNN3, the gene that encodes the small-conductance Ca2+-activated K+ channel 3 (SK3), possibly contributing to the electrical remodeling observed in AF (Ling et al., )

Regulation of proteins involved in structural remodeling by miRs

Fibrosis is the hallmark of structural cardiac remodeling (Allessie et al.,; Nguyen et al., ). Structural changes in the atria of AF patients have been identified (Anyukhovsky et al., ) at the level of cardiomyocytes and extracellular matrix (ECM), which predominately includes collagen types I and III, fibronectin, laminin, fibromodulin, and entactin (Goudis et al., ). ECM remodeling represents a maladaptive response to changes in myocardial structure and function during the progression of cardiac disease (Siwik and Colucci,; Dernellis and Panaretou, ). Degradation and deposition of ECM is a process dynamically regulated by a delicate balance (Goudis et al., ) between matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs).

In addition to the regulation of key proteins involved in electrical remodeling, miR-1 also modulate cardiac fibrosis, through means of its target protein Fibullin-2, a secreted protein implicated in ECM remodeling (Karakikes et al., ). An intriguing role for miR-21 and its downstream target Sprouty (Spry1), a master regulator of fibroblast survival and growth factor secretion, controlling the extent of interstitial fibrosis (Thum et al., ), has been demonstrated both in AF patients, in which atria miR-21 is increased, and murine models (Adam et al., ). This miR might also be involved in the apoptosis process and in inflammation (Ando et al., ). Several groups have recently proposed miR-29 as a mechanistic contributor in AF, through means a regulation of several proteins involved in cardiac fibrosis and apoptosis (Straten and Andersen,; Dawson et al.,; Hale and Levis, ).

Another potential therapeutic target to modulate fibrosis in AF is miR-30, which expression is down-regulated in AF. This miR directly interacts with the 3′ untranslated region of the connective tissue growth factor (CTGF), a key profibrotic protein (Duisters et al., ). The same group also proposed miR-133 as a modulator of CTGF protein levels (Duisters et al., ). Of interest, the same miR-133, which levels are reduced in AF patients (Cooley et al., ), is involved in the regulation of apoptosis and TGF-β signaling (Goette, ).

Conclusive remarks

Mounting evidence demonstrates that miRs are becoming one of the most fascinating areas of biology, given their critical roles in fine-tuning of physiological processes and their deregulation in several disorders, including AF. The relative role of different miRs in AF may also depend on the underlying etiology of AF, as the rhythm is an end stage manifestation of multiple, distinct predisposing pathological changes. The functional role of miRs as direct or indirect post-transcriptional regulators of genes implied in electrical and/or structural remodeling strongly suggest that these miRs may serve as potential biomarkers or promising drug targets, in prevention, treatment, and management of AF.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 128

  1. 1.

    Adam O. Lohfelm B. Thum T. Gupta S. K. Puhl S. L. Schafers H. J. (2012 ). Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res. Cardiol. 107, 278

    Not in our library10.1007/s00395-012-0278-0

  2. 2.

    Akerman A. W. Mukherjee R. (2013 ). MicroRNAs emerging as mediators of remodeling with atrial fibrillation. Heart Rhythm 10, 1010–1011

    Not in our library10.1016/j.hrthm.2013.03.021

  3. 3.

    Ali R. Huang Y. Maher S. E. Kim R. W. Giordano F. J. Tellides G. (2012 ). miR-1 mediated suppression of Sorcin regulates myocardial contractility through modulation of Ca2+ signaling. J. Mol. Cell. Cardiol. 52, 1027–1037

    Not in our library10.1016/j.yjmcc.2012.01.020

  4. 4.

    Allessie M. Ausma J. Schotten U. (2002 ). Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc. Res. 54, 230–246

    Not in our library10.1016/s0008-6363(02)00258-4

  5. 5.

    Ambros V. (2004 ). The functions of animal microRNAs. Nature 431, 350–355

    Not in our library10.1038/nature02871

  6. 6.

    Ambros V. Bartel B. Bartel D. P. Burge C. B. Carrington J. C. Chen X. (2003 ). A uniform system for microRNA annotation. RNA 9, 277–279

    Not in our library10.1261/rna.2183803

  7. 7.

    Anderson M. E. Mohler P. J. (2007 ). MicroRNA may have macro effect on sudden death. Nat. Med. 13, 410–411

    Not in our library10.1038/nm0407-410

  8. 8.

    Ando Y. Yang G. X. Kenny T. P. Kawata K. Zhang W. Huang W. (2013 ). Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-beta receptor type II mouse. J. Autoimmun. 41, 111–119

    Not in our library10.1016/j.jaut.2012.12.013

  9. 9.

    Anyukhovsky E. P. Sosunov E. A. Chandra P. Rosen T. S. Boyden P. A. Danilo P. (2005 ). Age-associated changes in electrophysiologic remodeling: a potential contributor to initiation of atrial fibrillation. Cardiovasc. Res. 66, 353–363

    Not in our library10.1016/j.cardiores.2004.10.033

  10. 10.

    Bartel D. P. (2004 ). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297

    Not in our library10.1016/s0092-8674(04)00045-5

  11. 11.

    Beyerbach D. M. Zipes D. P. (2004 ). Mortality as an endpoint in atrial fibrillation. Heart Rhythm 1, B8–B18 discussion: B18–B19.

    Not in our library10.1016/j.hrthm.2004.04.018

  12. 12.

    Boon R. A. Iekushi K. Lechner S. Seeger T. Fischer A. Heydt S. (2013 ). MicroRNA-34a regulates cardiac ageing and function. Nature 495, 107–110

    Not in our library10.1038/nature11919

  13. 13.

    Brieger D. B. Freedman S. B. (2009 ). Delirium cordis: can we predict the onset of atrial fibrillation? Lancet 373, 698–700

    Not in our library10.1016/s0140-6736(09)60415-3

  14. 14.

    Brundel B. J. Van Gelder I. C. Henning R. H. Tuinenburg A. E. Wietses M. Grandjean J. G. (2001 ). Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels. J. Am. Coll. Cardiol. 37, 926–932

    Not in our library10.1016/s0735-1097(00)01195-5

  15. 15.

    Callis T. E. Pandya K. Seok H. Y. Tang R. H. Tatsuguchi M. Huang Z. P. (2009 ). MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 119, 2772–2786

    Not in our library10.1172/jci36154

  16. 16.

    Care A. Catalucci D. Felicetti F. Bonci D. Addario A. Gallo P. (2007 ). MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 13, 613–618

    Not in our library10.1038/nm1582

  17. 17.

    Conen D. Chae C. U. Glynn R. J. Tedrow U. B. Everett B. M. Buring J. E. (2011 ). Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA 305, 2080–2087

    Not in our library10.1001/jama.2011.659

  18. 18.

    Cooley N. Cowley M. J. Lin R. C. Marasco S. Wong C. Kaye D. M. (2012 ). Influence of atrial fibrillation on microRNA expression profiles in left and right atria from patients with valvular heart disease. Physiol. Genomics 44, 211–219

    Not in our library10.1152/physiolgenomics.00111.2011

  19. 19.

    Cullen B. R. (2004 ). Transcription and processing of human microRNA precursors. Mol. Cell 16, 861–865

    Not in our library10.1016/j.molcel.2004.12.002

  20. 20.

    D'Ascia S. L. D'Ascia C. Marino V. Lombardi A. Santulli R. Chiariello M. (2011 ). Cardiac resynchronisation therapy response predicts occurrence of atrial fibrillation in non-ischaemic dilated cardiomyopathy. Int. J. Clin. Pract. 65, 1149–1155

    Not in our library10.1111/j.1742-1241.2011.02732.x

  21. 21.

    D'Ascia S. L. Santulli G. Liguori V. Marino V. Arturo C. Chiariello M. (2010 ). Advanced algorithms can lead to electrocardiographic misinterpretations. Int. J. Cardiol. 141, e34–e36

    Not in our library10.1016/j.ijcard.2008.11.144

  22. 22.

    Dawson K. Wakili R. Ordog B. Clauss S. Chen Y. Iwasaki Y. (2013 ). MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation 127, 1466–1475, 1475e1–e28.

    Not in our library10.1161/circulationaha.112.001207

  23. 23.

    Delmar M. Makita N. (2012 ). Cardiac connexins, mutations and arrhythmias. Curr. Opin. Cardiol. 27, 236–241

    Not in our library10.1097/hco.0b013e328352220e

  24. 24.

    Den Hoed M. Eijgelsheim M. Esko T. Brundel B. J. Peal D. S. Evans D. M. (2013 ). Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat. Genet. 45, 621–631

    Not in our library10.1038/ng.2610

  25. 25.

    Denli A. M. Tops B. B. Plasterk R. H. Ketting R. F. Hannon G. J. (2004 ). Processing of primary microRNAs by the Microprocessor complex. Nature 432, 231–235

    Not in our library10.1038/nature03049

  26. 26.

    Dernellis J. Panaretou M. (2006 ). Effects of C-reactive protein and the third and fourth components of complement (C3 and C4) on incidence of atrial fibrillation. Am. J. Cardiol. 97, 245–248

    Not in our library10.1016/j.amjcard.2005.08.027

  27. 27.

    Dhamoon A. S. Jalife J. (2005 ). The inward rectifier current (IK1) controls cardiac excitability and is involved in arrhythmogenesis. Heart Rhythm 2, 316–324

    Not in our library10.1016/j.hrthm.2004.11.012

  28. 28.

    Duisters R. F. Tijsen A. J. Schroen B. Leenders J. J. Lentink V. Van Der Made I. (2009 ). miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 104, 170–178, 176p following 178.

    Not in our library10.1161/circresaha.108.182535

  29. 29.

    Dvinge H. Git A. Graf S. Salmon-Divon M. Curtis C. Sottoriva A. (2013 ). The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497, 378–382

    Not in our library10.1038/nature12108

  30. 30.

    Dweep H. Sticht C. Pandey P. Gretz N. (2011 ). miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J. Biomed. Inform. 44, 839–847

    Not in our library10.1016/j.jbi.2011.05.002

  31. 31.

    Fabian M. R. Sonenberg N. (2012 ). The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat. Struct. Mol. Biol. 19, 586–593

    Not in our library10.1038/nsmb.2296

  32. 32.

    Filipowicz W. Bhattacharyya S. N. Sonenberg N. (2008 ). Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9, 102–114

    Not in our library10.1038/nrg2290

  33. 33.

    Frezzetti D. De Menna M. Zoppoli P. Guerra C. Ferraro A. Bello A. M. (2011 ). Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 30, 275–286

    Not in our library10.1038/onc.2010.416

  34. 34.

    Friedman R. C. Farh K. K. Burge C. B. Bartel D. P. (2009 ). Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92–105

    Not in our library10.1101/gr.082701.108

  35. 35.

    Fye W. B. (2006 ). Tracing atrial fibrillation–100 years. N. Engl. J. Med. 355, 1412–1414

    Not in our library10.1056/nejmp068059

  36. 36.

    Gan Z. Rumsey J. Hazen B. C. Lai L. Leone T. C. Vega R. B. (2013 ). Nuclear receptor/microRNA circuitry links muscle fiber type to energy metabolism. J. Clin. Invest. 123, 2564–2575

    Not in our library10.1172/jci67652

  37. 37.

    Garg A. Akoum N. (2013 ). Atrial fibrillation and heart failure: beyond the heart rate. Curr. Opin. Cardiol. 28, 332–336

    Not in our library10.1097/hco.0b013e32835fb710

  38. 38.

    Girmatsion Z. Biliczki P. Bonauer A. Wimmer-Greinecker G. Scherer M. Moritz A. (2009 ). Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm 6, 1802–1809

    Not in our library10.1016/j.hrthm.2009.08.035

  39. 39.

    Goette A. (2009 ). Nicotine, atrial fibrosis, and atrial fibrillation: do microRNAs help to clear the smoke? Cardiovasc. Res. 83, 421–422

    Not in our library10.1093/cvr/cvp188

  40. 40.

    Goudis C. A. Kallergis E. M. Vardas P. E. (2012 ). Extracellular matrix alterations in the atria: insights into the mechanisms and perpetuation of atrial fibrillation. Europace 14, 623–630

    Not in our library10.1093/europace/eur398

  41. 41.

    Grueter C. E. Van Rooij E. Johnson B. A. Deleon S. M. Sutherland L. B. Qi X. (2012 ). A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 149, 671–683

    Not in our library10.1016/j.cell.2012.03.029

  42. 42.

    Guo H. Ingolia N. T. Weissman J. S. Bartel D. P. (2010 ). Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835–840

    Not in our library10.1038/nature09267

  43. 43.

    Haissaguerre M. Hocini M. Shah A. J. Derval N. Sacher F. Jais P. (2013 ). Noninvasive panoramic mapping of human atrial fibrillation mechanisms: a feasibility report. J. Cardiovasc. Electrophysiol. 24, 711–717

    Not in our library10.1111/jce.12075

  44. 44.

    Hale C. S. Levis W. R. (2013 ). MicroRNA-29 and an integrated understanding of atrial fibrillation. J. Drugs Dermatol. 12, 1083

    Not in our library

  45. 45.

    Heymans S. Corsten M. F. Verhesen W. Carai P. Van Leeuwen R. E. Custers K. (2013 ). Macrophage MicroRNA-155 promotes cardiac hypertrophy and failure. Circulation 128, 1420–1432

    Not in our library10.1161/circulationaha.112.001357

  46. 46.
    MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice · 2012
    No notice
  47. 47.

    Hsu S. D. Lin F. M. Wu W. Y. Liang C. Huang W. C. Chan W. L. (2011 ). miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 39, D163–D169

    Not in our library10.1093/nar/gkq1107

  48. 48.

    Huikuri H. V. (2008 ). Heart rate dynamics as a marker of vulnerability to atrial fibrillation. J. Cardiovasc. Electrophysiol. 19, 913–914

    Not in our library10.1111/j.1540-8167.2008.01197.x

  49. 49.

    Jalife J. (2011 ). Deja vu in the theories of atrial fibrillation dynamics. Cardiovasc. Res. 89, 766–775

    Not in our library10.1093/cvr/cvq364

  50. 50.
    Identification of microRNA-mRNA modules using microarray data · 2011
    Not checked
  51. 51.

    Kallen A. N. Ma J. Huang Y. (2012 ). Does Lin28 antagonize miRNA-mediated repression by displacing miRISC from target mRNAs? Front. Genet. 3:240

    Not in our library10.3389/fgene.2012.00240

  52. 52.

    Kapur S. Macrae C. A. (2013 ). The developmental basis of adult arrhythmia: atrial fibrillation as a paradigm. Front. Physiol. 4:221

    Not in our library10.3389/fphys.2013.00221

  53. 53.
    Therapeutic Cardiac‐Targeted Delivery of miR‐1 Reverses Pressure Overload–Induced Cardiac Hypertrophy and Attenuates Pathological Remodeling · 2013
    No notice
  54. 54.

    Kim G. H. (2013 ). MicroRNA regulation of cardiac conduction and arrhythmias. Transl. Res. 161, 381–392

    Not in our library10.1016/j.trsl.2012.12.004

  55. 55.

    Kochegarov A. Moses A. Lian W. Meyer J. Hanna M. C. Lemanski L. F. (2013 ). A new unique form of microRNA from human heart, microRNA-499c, promotes myofibril formation and rescues cardiac development in mutant axolotl embryos. J. Biomed. Sci. 20:20

    Not in our library10.1186/1423-0127-20-20

  56. 56.

    Kushnir A. Marks A. R. (2010 ). The ryanodine receptor in cardiac physiology and disease. Adv. Pharmacol. 59, 1–30

    Not in our library10.1016/s1054-3589(10)59001-x

  57. 57.

    Lagos-Quintana M. Rauhut R. Lendeckel W. Tuschl T. (2001 ). Identification of novel genes coding for small expressed RNAs. Science 294, 853–858

    Not in our library10.1126/science.1064921

  58. 58.

    Latronico M. V. Condorelli G. (2008 ). On the road to the definition of the cardiac miRNome in human disease states. J. Mol. Cell. Cardiol. 45, 162–164

    Not in our library10.1016/j.yjmcc.2008.05.018

  59. 59.

    Latronico M. V. Condorelli G. (2009 ). RNA silencing: small RNA-mediated posttranscriptional regulation of mRNA and the implications for heart electropathophysiology. J. Cardiovasc. Electrophysiol. 20, 230–237

    Not in our library10.1111/j.1540-8167.2008.01357.x

  60. 60.

    Latronico M. V. Condorelli G. (2013 ). MicroRNA-dependent control of the cardiac fibroblast secretome. Circ. Res. 113, 1099–1101

    Not in our library10.1161/circresaha.113.302566

  61. 61.

    Lee G. Kumar S. Teh A. Madry A. Spence S. Larobina M. (2013 ). Epicardial wave mapping in human long-lasting persistent atrial fibrillation: transient rotational circuits, complex wavefronts, and disorganized activity. Eur. Heart J. 35, 86–97

    Not in our library10.1093/eurheartj/eht267

  62. 62.

    Leucci E. Patella F. Waage J. Holmstrom K. Lindow M. Porse B. (2013 ). microRNA-9 targets the long non-coding RNA MALAT1 for degradation in the nucleus. Sci. Rep. 3:2535

    Not in our library10.1038/srep02535

  63. 63.

    Lewis B. P. Burge C. B. Bartel D. P. (2005 ). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15–20

    Not in our library10.1016/j.cell.2004.12.035

  64. 64.
    Characterization of microRNA expression profiles in normal human tissues · 2007
    No notice
  65. 65.

    Lindgren K. S. Pekka Raatikainen M. J. Juhani Airaksinen K. E. Huikuri H. V. (2003 ). Relationship between the frequency of paroxysmal episodes of atrial fibrillation and pulmonary venous flow pattern. Europace 5, 17–23

    Not in our library10.1053/eupc.2002.0285

  66. 66.

    Ling T. Y. Wang X. L. Chai Q. Lau T. W. Koestler C. M. Park S. J. (2013 ). Regulation of the SK3 channel by microRNA-499–potential role in atrial fibrillation. Heart Rhythm 10, 1001–1009

    Not in our library10.1016/j.hrthm.2013.03.005

  67. 67.

    Liu X. Jin D. Y. McManus M. T. Mourelatos Z. (2012 ). Precursor microRNA-programmed silencing complex assembly pathways in mammals. Mol. Cell 46, 507–517

    Not in our library10.1016/j.molcel.2012.03.010

  68. 68.

    Lu Y. Zhang Y. Wang N. Pan Z. Gao X. Zhang F. (2010 ). MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation 122, 2378–2387

    Not in our library10.1161/circulationaha.110.958967

  69. 69.

    Lund E. Guttinger S. Calado A. Dahlberg J. E. Kutay U. (2004 ). Nuclear export of microRNA precursors. Science 303, 95–98

    Not in our library10.1126/science.1090599

  70. 70.

    Luo X. Pan Z. Shan H. Xiao J. Sun X. Wang N. (2013 ). MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J. Clin. Invest. 123, 1939–1951

    Not in our library10.1172/jci62185

  71. 71.

    Mahida S. (2013 ). Transcription factors and atrial fibrillation. Cardiovasc. Res. [Epub ahead of print].

    Not in our library10.1093/cvr/cvt261

  72. 72.

    Marasovic M. Zocco M. Halic M. (2013 ). Argonaute and triman generate dicer-independent priRNAs and mature siRNAs to initiate heterochromatin formation. Mol. Cell. 52, 173–183

    Not in our library10.1016/j.molcel.2013.08.046

  73. 73.

    Meijer H. A. Kong Y. W. Lu W. T. Wilczynska A. Spriggs R. V. Robinson S. W. (2013 ). Translational repression and eIF4A2 activity are critical for microRNA-mediated gene regulation. Science 340, 82–85

    Not in our library10.1126/science.1231197

  74. 74.

    Menezes A. R. Lavie C. J. Dinicolantonio J. J. O'Keefe J. Morin D. P. Khatib S. (2013 ). Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. Mayo Clin. Proc. 88, 394–409

    Not in our library10.1016/j.mayocp.2013.01.022

  75. 75.

    Musa H. Carlton L. Klos M. Vikstrom K. Anumonwo J. Jalife J. (2013 ). Arrhythmogenesis in a novel murine model with KCNJ2 mutation of familial atrial fibrillation. Heart Rhythm 10, 1749

    Not in our library10.1016/j.hrthm.2013.09.077

  76. 76.

    Nguyen T. P. Qu Z. Weiss J. N. (2013 ). Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. J. Mol. Cell. Cardiol. [Epub ahead of print].

    Not in our library10.1016/j.yjmcc.2013.10.018

  77. 77.

    Nivala M. Ko C. Y. Nivala M. Weiss J. N. Qu Z. (2012 ). Criticality in intracellular calcium signaling in cardiac myocytes. Biophys. J. 102, 2433–2442

    Not in our library10.1016/j.bpj.2012.05.001

  78. 78.

    Papait R. Kunderfranco P. Stirparo G. G. Latronico M. V. Condorelli G. (2013 ). Long noncoding RNA: a new player of heart failure? J. Cardiovasc. Transl. Res. 6, 876–883

    Not in our library10.1007/s12265-013-9488-6

  79. 79.

    Perino A. Ghigo A. Ferrero E. Morello F. Santulli G. Baillie G. S. (2011 ). Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110gamma. Mol. Cell 42, 84–95

    Not in our library10.1016/j.molcel.2011.01.030

  80. 80.

    Pfaff J. Hennig J. Herzog F. Aebersold R. Sattler M. Niessing D. (2013 ). Structural features of Argonaute-GW182 protein interactions. Proc. Natl. Acad. Sci. U.S.A. 110, E3770–E3779

    Not in our library10.1073/pnas.1308510110

  81. 81.

    Qiao A. Khechaduri A. Kannan Mutharasan R. Wu R. Nagpal V. Ardehali H. (2013 ). MicroRNA-210 decreases heme levels by targeting ferrochelatase in cardiomyocytes. J. Am. Heart Assoc. 2:e000121

    Not in our library10.1161/jaha.113.000121

  82. 82.

    Quiat D. Olson E. N. (2013 ). MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J. Clin. Invest. 123, 11–18

    Not in our library10.1172/jci62876

  83. 83.

    Riley A. B. Manning W. J. (2011 ). Atrial fibrillation: an epidemic in the elderly. Expert Rev. Cardiovasc. Ther. 9, 1081–1090

    Not in our library10.1586/erc.11.107

  84. 84.

    Roth B. M. Ishimaru D. Hennig M. (2013 ). The core microprocessor component DiGeorge syndrome critical region 8 (DGCR8) is a nonspecific RNA-binding protein. J. Biol. Chem. 288, 26785–26799

    Not in our library10.1074/jbc.m112.446880

  85. 85.

    Ruby J. G. Jan C. H. Bartel D. P. (2007 ). Intronic microRNA precursors that bypass Drosha processing. Nature 448, 83–86

    Not in our library10.1038/nature05983

  86. 86.

    Ruvkun G. Ambros V. Coulson A. Waterston R. Sulston J. Horvitz H. R. (1989 ). Molecular genetics of the Caenorhabditis elegans heterochronic gene lin-14. Genetics 121, 501–516

    Not in our library10.1093/genetics/121.3.501

  87. 87.

    Ruvkun G. Giusto J. (1989 ). The Caenorhabditis elegans heterochronic gene lin-14 encodes a nuclear protein that forms a temporal developmental switch. Nature 338, 313–319

    Not in our library10.1038/338313a0

  88. 88.

    Ruwald A. C. Bloch Thomsen P. E. Gang U. Jorgensen R. M. Huikuri H. V. Jons C. (2013 ). New-onset atrial fibrillation predicts malignant arrhythmias in post-myocardial infarction patients-A Cardiac Arrhythmias and RIsk Stratification after acute Myocardial infarction (CARISMA) substudy. Am. Heart J. 166, 855–863e853.

    Not in our library10.1016/j.ahj.2013.08.017

  89. 89.

    Santulli G. (2012a ). Coronary heart disease risk factors and mortality. JAMA 307, 1137

    Not in our library10.1001/jama.2012.323

  90. 90.

    Santulli G. (2012b ). Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus. Neurology 78, 840

    Not in our library10.1212/wnl.0b013e31824de51b

  91. 91.

    Santulli G. (2013 ). Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts. J. Cardiovasc. Dis. 1, 1–2

    Not in our library

  92. 92.
    Physical activity ameliorates cardiovascular health in elderly subjects: the functional role of the β adrenergic system · 2013
    Not checked
  93. 93.

    Santulli G. D'Ascia C. (2012 ). Atrial remodelling in echocardiographic super-responders to cardiac resynchronization therapy. Heart 98, 517

    Not in our library10.1136/heartjnl-2012-301731

  94. 94.

    Santulli G. D'Ascia S. D'Ascia C. (2012a ). Regarding the impact of left ventricular size on response to cardiac resynchronization therapy. Am. Heart J. 163, e11

    Not in our library10.1016/j.ahj.2012.01.001

  95. 95.

    Santulli G. D'Ascia S. L. D'Ascia C. (2012b ). Development of atrial fibrillation in recipients of cardiac resynchronization therapy: the role of atrial reverse remodelling. Can. J. Cardiol. 28, 245.e217

    Not in our library10.1016/j.cjca.2011.11.001

  96. 96.

    Santulli G. D'Ascia S. Marino V. D'Ascia C. (2012c ). Atrial function in patients undergoing CRT. JACC Cardiovasc. Imaging 5, 124–125

    Not in our library10.1016/j.jcmg.2011.11.002

  97. 97.

    Santulli G. Iaccarino G. (2013 ). Pinpointing beta adrenergic receptor in ageing pathophysiology: victim or executioner? Evidence from crime scenes. Immun. Ageing 10:10

    Not in our library10.1186/1742-4933-10-10

  98. 98.

    Santulli G. Totary-Jain H. (2013 ). Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Pharmacogenomics 14, 1517–1526

    Not in our library10.2217/pgs.13.143

  99. 99.

    Saxena A. Tabin C. J. (2010 ). miRNA-processing enzyme Dicer is necessary for cardiac outflow tract alignment and chamber septation. Proc. Natl. Acad. Sci. U.S.A. 107, 87–91

    Not in our library10.1073/pnas.0912870107

  100. 100.

    Shah A. J. Hocini M. Xhaet O. Pascale P. Roten L. Wilton S. B. (2013 ). Validation of novel 3-dimensional electrocardiographic mapping of atrial tachycardias by invasive mapping and ablation: a multicenter study. J. Am. Coll. Cardiol. 62, 889–897

    Not in our library10.1016/j.jacc.2013.03.082

  101. 101.

    Shan H. Li X. Pan Z. Zhang L. Cai B. Zhang Y. (2009 ). Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1. Br. J. Pharmacol. 158, 1227–1235

    Not in our library10.1111/j.1476-5381.2009.00377.x

  102. 102.

    Shen J. Xia W. Khotskaya Y. B. Huo L. Nakanishi K. Lim S. O. (2013 ). EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 497, 383–387

    Not in our library10.1038/nature12080

  103. 103.

    Shiohama A. Sasaki T. Noda S. Minoshima S. Shimizu N. (2003 ). Molecular cloning and expression analysis of a novel gene DGCR8 located in the DiGeorge syndrome chromosomal region. Biochem. Biophys. Res. Commun. 304, 184–190

    Not in our library10.1016/s0006-291x(03)00554-0

  104. 104.

    Siomi H. Siomi M. C. (2009 ). On the road to reading the RNA-interference code. Nature 457, 396–404

    Not in our library10.1038/nature07754

  105. 105.

    Siwik D. A. Colucci W. S. (2004 ). Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail. Rev. 9, 43–51

    Not in our library10.1023/b:hrev.0000011393.40674.13

  106. 106.

    Slagsvold K. H. Rognmo O. Hoydal M. A. Wisloff U. Wahba A. (2013 ). Remote ischemic preconditioning preserves mitochondrial function and influences myocardial microRNA expression in atrial myocardium during coronary bypass surgery. Circ. Res. [Epub ahead of print].

    Not in our library10.1161/circresaha.114.302751

  107. 107.

    Song S. J. Poliseno L. Song M. S. Ala U. Webster K. Ng C. (2013 ). MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 154, 311–324

    Not in our library10.1016/j.cell.2013.06.026

  108. 108.

    Straten P. Andersen M. H. (2010 ). The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens. Oncotarget 1, 239–245

    Not in our library10.18632/oncotarget.134

  109. 109.

    Ter Keurs H. E. Boyden P. A. (2007 ). Calcium and arrhythmogenesis. Physiol. Rev. 87, 457–506

    Not in our library10.1152/physrev.00011.2006

  110. 110.

    Thomas I. C. Sorrentino M. J. (2014 ). Bleeding risk prediction models in atrial fibrillation. Curr. Cardiol. Rep. 16, 432

    Not in our library10.1007/s11886-013-0432-9

  111. 111.

    Thum T. Gross C. Fiedler J. Fischer T. Kissler S. Bussen M. (2008 ). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980–984

    Not in our library10.1038/nature07511

  112. 112.

    Tritsch E. Mallat Y. Lefebvre F. Diguet N. Escoubet B. Blanc J. (2013 ). An SRF/miR-1 axis regulates NCX1 and Annexin A5 protein levels in the normal and failing heart. Cardiovasc. Res. 98, 372–380

    Not in our library10.1093/cvr/cvt042

  113. 113.

    Van Rooij E. Olson E. N. (2012 ). MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11, 860–872

    Not in our library10.1038/nrd3864

  114. 114.

    Vikman S. Lindgren K. Makikallio T. H. Yli-Mayry S. Airaksinen K. E. Huikuri H. V. (2005 ). Heart rate turbulence after atrial premature beats before spontaneous onset of atrial fibrillation. J. Am. Coll. Cardiol. 45, 278–284

    Not in our library10.1016/j.jacc.2004.10.033

  115. 115.

    Von Brandenstein M. Richter C. Fries J. W. (2012 ). MicroRNAs: small but amazing, and their association with endothelin. Life Sci. 91, 475–489

    Not in our library10.1016/j.lfs.2012.06.025

  116. 116.

    Wang Z. Lu Y. Yang B. (2011 ). MicroRNAs and atrial fibrillation: new fundamentals. Cardiovasc. Res. 89, 710–721

    Not in our library10.1093/cvr/cvq350

  117. 117.
    Practical Aspects of microRNA Target Prediction · 2011
    No notice
  118. 118.

    Wu P. H. Isaji M. Carthew R. W. (2013 ). Functionally diverse microRNA effector complexes are regulated by extracellular signaling. Mol. Cell 52, 113–123

    Not in our library10.1016/j.molcel.2013.08.023

  119. 119.

    Xie W. Santulli G. Guo X. Gao M. Chen B. X. Marks A. R. (2013 ). Imaging atrial arrhythmic intracellular calcium in intact heart. J. Mol. Cell. Cardiol. 64, 120–123

    Not in our library10.1016/j.yjmcc.2013.09.003

  120. 120.

    Yang B. Lin H. Xiao J. Lu Y. Luo X. Li B. (2007 ). The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat. Med. 13, 486–491

    Not in our library10.1038/nm1569

  121. 121.

    Yates L. A. Norbury C. J. Gilbert R. J. (2013 ). The long and short of microRNA. Cell 153, 516–519

    Not in our library10.1016/j.cell.2013.04.003

  122. 122.

    Zacharewicz E. Lamon S. Russell A. P. (2013 ). MicroRNAs in skeletal muscle and their regulation with exercise, ageing, and disease. Front. Physiol. 4:266

    Not in our library10.3389/fphys.2013.00266

  123. 123.

    Zemlin C. W. Pertsov A. M. (2007 ). Bradycardic onset of spiral wave re-entry: structural substrates. Europace 9(Suppl. 6), vi59–vi63

    Not in our library10.1093/europace/eum205

  124. 124.

    Zeng Y. Yi R. Cullen B. R. (2005 ). Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme Drosha. EMBO J. 24, 138–148

    Not in our library10.1038/sj.emboj.7600491

  125. 125.

    Zhang R. Niu H. Ban T. Xu L. Li Y. Wang N. (2013a ). Elevated plasma microRNA-1 predicts heart failure after acute myocardial infarction. Int. J. Cardiol. 166, 259–260

    Not in our library10.1016/j.ijcard.2012.09.108

  126. 126.

    Zhang Y. Sun L. Zhang Y. Liang H. Li X. Cai R. (2013b ). Overexpression of microRNA-1 causes atrioventricular block in rodents. Int. J. Biol. Sci. 9, 455–462

    Not in our library10.7150/ijbs.4630

  127. 127.

    Zhang Y. Huang Z. J. Dai D. Z. Feng Y. Na T. Tang X. Y. (2008 ). Downregulated FKBP12.6 expression and upregulated endothelin signaling contribute to elevated diastolic calcium and arrhythmogenesis in rat cardiomyopathy produced by l-thyroxin. Int. J. Cardiol. 130, 463–471

    Not in our library10.1016/j.ijcard.2008.05.018

  128. 128.

    Zhao Y. Ransom J. F. Li A. Vedantham V. Von Drehle M. Muth A. N. (2007 ). Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129, 303–317

    Not in our library10.1016/j.cell.2007.03.030

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.